Infant Bacterial Therapeutics AB (publ) Total Assets
Infant Bacterial Therapeutics AB (publ) total assets. Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) holds total assets worth Skr178.23 Million SEK (≈ $19.18 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Infant Bacterial Therapeutics AB (publ) (IBT-B) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Infant Bacterial Therapeutics AB (publ) (2012–2024)
Total assets of Infant Bacterial Therapeutics AB (publ) from 2012 to 2024. This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s total assets have evolved over time, based on quarterly financial data. See IBT-B stock price and chart for real-time trading data and today's change.
Infant Bacterial Therapeutics AB (publ) - Asset Composition Analysis
Infant Bacterial Therapeutics AB (publ) Total Assets Breakdown (December 2024)
Infant Bacterial Therapeutics AB (publ) total assets breakdown as of December 2024. Infant Bacterial Therapeutics AB (publ)'s total assets of Skr178.23 Million consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr223.39 Million | 93.3% |
| Accounts Receivable | Skr4.77 Million | 2.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr8.89 Million | 3.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IBT-B net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Infant Bacterial Therapeutics AB (publ)'s current assets represent 96.3% of total assets in 2024, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 93.3% of total assets in 2024, down from 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is cash and equivalents at 93.3% of total assets.
Infant Bacterial Therapeutics AB (publ) Competitors by Total Assets
Key competitors of Infant Bacterial Therapeutics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Infant Bacterial Therapeutics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.15 | 6.52 | 43.10 |
| Quick Ratio | 3.15 | 6.52 | 43.10 |
| Cash Ratio | 0.00 | 6.41 | 0.00 |
| Working Capital | Skr116.02 Million | Skr194.87 Million | Skr427.95 Million |
Infant Bacterial Therapeutics AB (publ) - Advanced Valuation Insights
This section examines the relationship between Infant Bacterial Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.49 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -31.8% |
| Total Assets | Skr239.57 Million |
| Market Capitalization | $108.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Infant Bacterial Therapeutics AB (publ)'s assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Infant Bacterial Therapeutics AB (publ)'s assets decreased by 31.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Infant Bacterial Therapeutics AB (publ) (2012–2024)
The table below shows the annual total assets of Infant Bacterial Therapeutics AB (publ) from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr239.57 Million ≈ $25.78 Million |
-31.81% |
| 2023-12-31 | Skr351.33 Million ≈ $37.81 Million |
+0.49% |
| 2022-12-31 | Skr349.62 Million ≈ $37.62 Million |
-14.41% |
| 2021-12-31 | Skr408.48 Million ≈ $43.96 Million |
-9.29% |
| 2020-12-31 | Skr450.32 Million ≈ $48.46 Million |
-13.11% |
| 2019-12-31 | Skr518.27 Million ≈ $55.77 Million |
-8.01% |
| 2018-12-31 | Skr563.37 Million ≈ $60.63 Million |
+221.88% |
| 2017-12-31 | Skr175.02 Million ≈ $18.84 Million |
+58.96% |
| 2016-12-31 | Skr110.11 Million ≈ $11.85 Million |
+33.40% |
| 2015-12-31 | Skr82.54 Million ≈ $8.88 Million |
+467.81% |
| 2014-12-31 | Skr14.54 Million ≈ $1.56 Million |
+1027.91% |
| 2013-12-31 | Skr1.29 Million ≈ $138.70K |
+2576.57% |
| 2012-12-31 | Skr48.15K ≈ $5.18K |
-- |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more